CA3241852A1 - Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections - Google Patents
Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infectionsInfo
- Publication number
- CA3241852A1 CA3241852A1 CA3241852A CA3241852A CA3241852A1 CA 3241852 A1 CA3241852 A1 CA 3241852A1 CA 3241852 A CA3241852 A CA 3241852A CA 3241852 A CA3241852 A CA 3241852A CA 3241852 A1 CA3241852 A1 CA 3241852A1
- Authority
- CA
- Canada
- Prior art keywords
- aat
- fragment
- protein
- recombinant
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/84—Pichia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21216836 | 2021-12-22 | ||
| EP21216836.3 | 2021-12-22 | ||
| EP22166483.2 | 2022-04-04 | ||
| EP22166483 | 2022-04-04 | ||
| PCT/EP2022/087461 WO2023118424A1 (en) | 2021-12-22 | 2022-12-22 | Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3241852A1 true CA3241852A1 (en) | 2023-06-29 |
Family
ID=84980906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3241852A Pending CA3241852A1 (en) | 2021-12-22 | 2022-12-22 | Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250057927A1 (https=) |
| EP (1) | EP4453233A1 (https=) |
| JP (1) | JP2025501746A (https=) |
| AU (1) | AU2022422304A1 (https=) |
| CA (1) | CA3241852A1 (https=) |
| IL (1) | IL313247A (https=) |
| TW (1) | TW202334430A (https=) |
| WO (1) | WO2023118424A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4480960A1 (en) * | 2023-06-22 | 2024-12-25 | AATEC Medical GmbH | A recombinant human alpha-1 antitrypsin glycoprotein |
| EP4730999A1 (en) * | 2023-06-22 | 2026-04-29 | AATEC Medical GmbH | Recombinant aat from yeast to treat transplants |
| CN121752288A (zh) * | 2023-06-22 | 2026-03-27 | 阿泰克医疗有限公司 | 重组人α-1抗胰蛋白酶糖蛋白 |
| WO2024261179A1 (en) * | 2023-06-22 | 2024-12-26 | Aatec Medical Gmbh | Recombinant aat from yeast to treat bacterial respiratory infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713249A (en) | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
| US5266333A (en) | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
| US5417982A (en) | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| WO2021191900A1 (en) | 2020-03-26 | 2021-09-30 | Kamada Ltd. | Methods for treating infectious diseases caused by coronavirus |
-
2022
- 2022-12-22 TW TW111149485A patent/TW202334430A/zh unknown
- 2022-12-22 EP EP22843749.7A patent/EP4453233A1/en active Pending
- 2022-12-22 AU AU2022422304A patent/AU2022422304A1/en active Pending
- 2022-12-22 US US18/723,224 patent/US20250057927A1/en active Pending
- 2022-12-22 JP JP2024537865A patent/JP2025501746A/ja active Pending
- 2022-12-22 IL IL313247A patent/IL313247A/en unknown
- 2022-12-22 CA CA3241852A patent/CA3241852A1/en active Pending
- 2022-12-22 WO PCT/EP2022/087461 patent/WO2023118424A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20250057927A1 (en) | 2025-02-20 |
| JP2025501746A (ja) | 2025-01-23 |
| TW202334430A (zh) | 2023-09-01 |
| EP4453233A1 (en) | 2024-10-30 |
| IL313247A (en) | 2024-08-01 |
| WO2023118424A1 (en) | 2023-06-29 |
| AU2022422304A1 (en) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250057927A1 (en) | Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections | |
| US20230414730A1 (en) | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections | |
| KR20160054475A (ko) | 흡연의 해로운 영향을 감소시키는 신규의 수단 | |
| JP6030201B2 (ja) | α‐１プロテイナーゼインヒビターのための組成物、方法およびキット | |
| KR20160132021A (ko) | 건조 분말 펩티드 약제 | |
| CN101333258A (zh) | 一种具有抗菌及促伤口愈合功能的融合多肽 | |
| WO2022074656A1 (en) | Long-acting dnase | |
| CN118434880A (zh) | 由酵母生产的α-1抗胰蛋白酶用于治疗病毒感染的用途 | |
| WO2021164576A1 (zh) | 用于抗冠状病毒感染的药物及其应用 | |
| EP4480960A1 (en) | A recombinant human alpha-1 antitrypsin glycoprotein | |
| EP3995130A1 (en) | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections | |
| KR20260030111A (ko) | 재조합 인간 알파-1 항트립신 당단백질 | |
| CN116217697A (zh) | 一种重组人角质细胞生长因子-2及其制备方法和应用 | |
| IL325205A (en) | Recombinant human alpha-1 antitrypsin glycoprotein for use in the treatment of inflammatory lung diseases | |
| WO2024261179A1 (en) | Recombinant aat from yeast to treat bacterial respiratory infections | |
| CN107904251A (zh) | TAT‑hEGF融合蛋白的制备及其在隐形面膜的应用 | |
| AU2022380713A1 (en) | Das181 variant compositions | |
| KR20080071116A (ko) | 기도에 영향을 미치는 염증 질환에 있어서 활성화 단백질ｃ의 기도 투여법 | |
| JP2008308438A (ja) | 新規なインフルエンザ治療および／または予防薬 | |
| HK40090471A (zh) | Ace2-fc融合蛋白及其用途 | |
| CN121653105A (zh) | 中性粒细胞弹性蛋白酶的融合蛋白及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED Effective date: 20240704 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241118 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241210 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251216 |